Purple Biotech (PPBT) has released an update.
Purple Biotech LTD. announced a legal victory as the Tel Aviv District Court dismissed a class action lawsuit against the company and its directors concerning alleged misleading information about their drug, Consensi. The legal dismissal concludes the proceedings of the 2017 Motion, with the court mandating each party to cover their own court expenses. This development could impact Purple Biotech’s market perception and investor confidence.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
